Activating transcription factor 2 and c-Jun-mediated induction of FoxP3 for experimental therapy of mammary tumor in the mouse

Cancer Research

Volumn 69, Issue 14, 2009, Pages 5954-5960

  Liu, Yan ^a   Wang, Yin ^a   Li, Weiquan ^a   Zheng, Pan ^a,b   Liu, Yang ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; ANISOMYCIN; SHORT HAIRPIN RNA; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST EPITHELIUM; BREAST TUMOR; CONTROLLED STUDY; EMBRYO; EXPERIMENTAL THERAPY; FEMALE; GENE LOCUS; GENE SILENCING; INTRON; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACTIVATING TRANSCRIPTION FACTOR 2; ANIMALS; ANISOMYCIN; APOPTOSIS; BINDING SITES; BLOTTING, WESTERN; CELL LINE, TUMOR; CELLS, CULTURED; CHROMATIN IMMUNOPRECIPITATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENHANCER ELEMENTS, GENETIC; ENZYME INHIBITORS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED STRAINS; MICE, KNOCKOUT; PROTEIN SYNTHESIS INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

EID: 67651002347     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0778     Document Type: Article

References (25)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Knudson AG, Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci US A 1971;68:820-3.
3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
4. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
5. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
6. Spatz A, Borg C, Feunteun J. X-chromosome genetics and human cancer. Nature reviews 2004;4:617-29.
7. Zuo T, Wang L, Morrison C, et al. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of HER-2/ErbB2 oncogene. Cell 2007;129:1275-86.
8. Rivera MN, Kim WJ, Wells J, et al. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 2007;315:642-5.
9. Bykov VJ, Issaeva N, Shilov A, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002;8:282-8.
10. Maekawa T, Shinagawa T, Sano Y, et al. Reduced levels of ATF-2 predispose mice to mammary tumors. Mol Cell Biol 2007;27:1730-44.
11. Reimold AM, Grusby MJ, Kosaras B, et al. Chondrodysplasia and neurological abnormalities in ATF-2-deficient mice. Nature 1996;379:262-5.
12. Wang CY, Cusack JC, Jr., Liu R, Baldwin AS, Jr. Control of inducible chemoresistance: enhanced antitumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 1999;5:412-7.
13. Im H, Grass JA, Johnson KD, Boyer ME, Wu J, Bresnick EH. Measurement of protein-DNA interactions in vivo by chromatin immunoprecipitation. Methods Mol Biol 2004;284:129-46.
14. Wang Y, Liu Y, Wu C, McNally B, Liu Y, Zheng P. Laforin confers cancer resistance to energy deprivation-induced apoptosis. Cancer Res 2008;68:4039-44.
15. Zuo T, Liu R, Zhang H, et al. FOXP3 is a novel transcription repressor for the breast cancer oncogene SKP2. J Clin Invest 2007;117:3765-73.
16. Su B, Jacinto E, Hibi M, Kallunki T, Karin M, Ben-Neriah Y. JNK is involved in signal integration during costimulation of T lymphocytes. Cell 1994;77:727-36.
17. Tommasini A, Ferrari S, Moratto D, et al. X-chromosome inactivation analysis in a female carrier of FOXP3 mutation. Clin Exp Immunol 2002;130:127-30.
18. Rahman I. Oxidative stress and gene transcription in asthma and chronic obstructive pulmonary disease: antioxidant therapeutic targets. Curr Drug Targets 2002;1:291-315.
19. Tsai CL, Li HP, Lu YJ, et al. Activation of DNA methyltransferase 1 by EBV LMP1 Involves c-Jun NH(2)-terminal kinase signaling. Cancer Res 2006;66:11668-76.
20. Chen GY, Chen C, Wang L, Chang X, Zheng P, Liu Y. Cutting edge: Broad expression of the FoxP3 locus in epithelial cells: a caution against early Interpretation of fatal inflammatory diseases following in vivo depletion of FoxP3-expressing cells. J Immunol 2008;180:5163-6.
21. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330-6.
22. Floess S, Freyer J, Siewert C, et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 2007;5:e38.
23. Kim HP, Leonard WJ. CREB/ATF-dependent T cell receptor-induced FoxP3 gene expression: a role for DNA methylation. J Exp Med 2007;204:1543-51.
24. Tone Y, Furuuchi K, Kojima Y, Tykocinski ML, Greene MI, Tone M. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol 2008;9:194-202.
25. Venuprasad K, Huang H, Harada Y, et al. The E3 ubiquitin ligase Itch regulates expression of transcription factor Foxp3 and airway inflammation by enhancing the function of transcription factor TIEG1. Nat Immunol 2008;9:245-53.